Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
PERCODAN-DEMI is a combination analgesic tablet containing aspirin and two forms of oxycodone (hydrochloride and terephthalate), an opioid pain reliever. It is indicated for moderate pain relief and combines a non-opioid (aspirin) with an opioid (oxycodone) for enhanced analgesia. The combination mechanism leverages both peripheral anti-inflammatory and central opioid receptor effects.
As a decades-old product approaching loss of exclusivity with moderate competitive pressure (30%), career opportunities are limited to legacy support and transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PERCODAN-DEMI offers minimal career growth potential given its LOE-approaching status and zero linked job openings. Roles available are primarily defensive in nature, focused on managing the product through patent cliff and generic transition rather than driving innovation or market expansion.
Worked on PERCODAN-DEMI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.